Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

doi:10.1038/s41467-026-68324-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Nature communications - 10 Feb 2026

Huff Amanda L, Haldar S Daniel, Girgis Alexander A, Wang Hejia Henry, Danilova Ludmila, Heumann Thatcher, Berg Maureen, Wang Yuxuan, Andaloori Lalitya, Hernandez Alexei, Longway Gabriella, Barrett Benjamin, Zhu Zirui, Davis-Marcisak Emily, Thoburn Christopher, Leatherman James, Mitchell Sarah, Lee Jae W, Shu Daniel H, Konig Maximillian F, Mog Brian J, Montagne Janelle, Coyne Erin M, Bever Katherine, Baretti Marina, Yarchoan Mark, Anders Robert A, Kagohara Luciane T, Laheru Daniel, Thomas Amy M, Durham Jennifer, Nauroth Julie M, Lu Jiayun, Wang Hao, Fertig Elana J, Ho Won Jin, Azad Nilofer S, Jaffee Elizabeth M, Zaidi Neeha

Abstract excerpt

In this phase I study, we test a pooled synthetic long peptide vaccine targeting the six KRAS mutations (G12V, G12A, G12R, G12C, G12D, G13D) with ipilimumab and nivolumab in resected pancreatic adenocarcinoma. Co-primary endpoints include safety and maximal percent change of IFNγ-producing mutant KRAS T cell responses in the blood within 17 weeks. Secondary endpoints include disease-free survival, overall...

Topics

Humans
Pancreatic Neoplasms
Cancer Vaccines
Proto-Oncogene Proteins p21(ras)
Mutation
Female
Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Middle Aged

Male

Immune Checkpoint Inhibitors

Protein Subunit Vaccines

Interferon-gamma

Ipilimumab

CD8-Positive T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 41667470
DOI: 10.1038/s41467-026-68324-4
PMCID: PMC12891733

Genes

KRAS
CD4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.